XBI - SPDR S&P Biotech ETF

NYSEArca - NYSEArca Delayed Price. Currency in USD
81.49
-1.53 (-1.84%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close83.02
Open83.11
Bid0.00 x 3200
Ask0.00 x 1000
Day's Range81.45 - 83.11
52 Week Range64.38 - 101.55
Volume2,884,114
Avg. Volume5,007,663
Net Assets3.86B
NAV81.44
PE Ratio (TTM)N/A
Yield0.18%
YTD Return13.05%
Beta (3Y Monthly)1.69
Expense Ratio (net)0.35%
Inception Date2006-01-31
Trade prices are not sourced from all markets
  • The sectors investors rushed back into after sell-off
    CNBC Videoslast month

    The sectors investors rushed back into after sell-off

    CNBC's Mike Santoli breaks down the sectors investors are buying into after trade tensions lowered markets.

  • TheStreet.com6 days ago

    Stalking Entry Points in the XBI Biotech ETF

    If you read my update last week, you know that we were looking for a possible resumption of the $SPX cash on a pullback to the December lows. Although the first key support was violated on the way down, the second general zone held up and was followed with a 30-minute buy trigger that is described in the trigger video, below.

  • Biotech Sector Could Enter Bear Market
    Investopedia12 days ago

    Biotech Sector Could Enter Bear Market

    Institutional players are abandoning biotech funds at a rapid pace, raising the odds that the sector will enter a bear market.

  • Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?
    Zacks17 days ago

    Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?

    Sector ETF report for PBE

  • ETF Trends18 days ago

    Why Biotech ETF is Usually a Summer Winner

    The summer months can be unkind to the broader market, but some sector and industry funds perform well as temperatures heat up. The SPDR S&P Biotech ETF (XBI) , one of the largest biotechnology exchange traded funds (ETFs), has a rich history of delivering summer upside. Healthcare stocks are also showing attractive valuations relative to other defensive sectors, which are richly valued.

  • Benzingalast month

    FDA Issues Final Guidelines To Make Interchangeable Biosimilars More Easily Available

    The FDA's latest guidelines outlined the studies a company making a biosimilar — a copycat version of the pricey biologic — should conduct to obtain the interchangeable designation. A biologic can cost up to hundreds or thousands of dollars for some chronic conditions. "This guidance is intended to assist sponsors in demonstrating that a proposed therapeutic protein product is interchangeable with a reference product for the purposes of submitting a marketing application or supplement," the FDA said.

  • These 3 revolutionary genomics companies are changing lives for patients — and investors
    MarketWatchlast month

    These 3 revolutionary genomics companies are changing lives for patients — and investors

    While we can research the family tree for these health issues, it’s been difficult to know for sure what could happen — until now. Because of breakthroughs in human genome mapping, we can now get a clear line of sight on what diseases are coming our way — and the insights are only getting better.

  • These 6 biotech stocks are promising takeover targets
    MarketWatchlast month

    These 6 biotech stocks are promising takeover targets

    With sector weakness since early April shaving 8%-10% off the iShares NASDAQ Biotechnology ETF (IBB) and the SPDR S&P Biotech ETF (XBI) for example, potential takeover targets in fact are now more attractive. Large pharma and biotech companies need to build out their product pipelines, and many have the buying power to make acquisitions. "The appetite for M&A is still high," says Jared Holz, of the healthcare sector trading desk at Jefferies.

  • Benzinga2 months ago

    Attention Biotech Investors: Mark Your Calendar For These May PDUFA Dates

    Biotech stocks bucked the broader market uptrend in April, thanks to the volatility associated with the sector. Some of the catalysts that drove stocks include clinical trial readouts, capital raising ...

  • Barrons.com2 months ago

    Gilead Stock Is Due for a Comeback, Analyst Says

    Gilead investors have had their patience tried lately. While the company’s peers tracked by the  (XBI) and the  (IBB) (IBB) have enjoyed double-digit gains year to date, along with the broader market, Gilead stock is up an anemic 4.2% since the start of the year. Gilead still earns plenty of analyst praise, and new leadership has sparked some enthusiasm.

  • S&P 500 Hit New Records: Buy These High-Beta ETFs & Stocks
    Zacks2 months ago

    S&P 500 Hit New Records: Buy These High-Beta ETFs & Stocks

    High-beta ETFs & stocks seek to capitalize on continued growth with market-beating returns.

  • TheStreet.com2 months ago

    A Tough Week for Biotech, the Candidates' Whipping Boy Again

    Biotech was particularly hit hard as "Medicare for All" and other possible government intervention across the industry received more attention as we get deeper in the 2020 election cycle. Unfortunately, algorithmic trading has become part of life in the market in recent years. On any given day up to 80% of the market's overall trading volume can be driven by computer-generated program trading.

  • ETF Trends2 months ago

    Biotech ETFs: Destinations For Investing in Innovation

    The SPDR S&P Biotech ETF (XBI) , one of the largest biotechnology exchange traded funds (ETFs), is up more than 24% this year, indicating the biotech space remains in favor as investors look for avenues to access innovative concepts and themes. Healthcare stocks are also showing attractive valuations relative to other defensive sectors, which are richly valued. Biotechnology historically trades at multiples that are elevated relative to broader benchmarks, but after last year’s of struggles for biotechnology names, some analysts see value with some big-name biotech stocks.

  • ETF Trends2 months ago

    Healthcare, Biotech ETFs Plunge on Mounting Political Pressures

    Healthcare stocks and sector-related exchange traded funds took a heavy blow Wednesday, trailing the broader market by a historic margin early in 2019, as political risks on Capitol Hill ramped up. The sector's latest drop has been attributed to a number of signs that politicians on both sides of the aisle in Congress are eyeing tighter regulations ahead of the 2020 presidential election, the Wall Street Journal reports. Insurers have also taken the brunt of the hit and was among the market's worst performers in recent trading amid uncertainty over the future of the U.S. healthcare policy, with UnitedHealth on pace for its worst month in a decade as the "Medicare for All" mantra weighs on investment confidence.

  • ETF Trends2 months ago

    Tom Lydon on Yahoo Finance Live: SPY, Health Care, EM, and What to Avoid

    For exchange-traded fund (ETF) investors, the  SPDR S&P 500 ETF (SPY) has been a dietary staple for many years. After posting $4.1 billion of outflows during the first quarter, SPY, the largest ETF that tracks the S&P 500, attracted more than $5.3 billion of inflows to start the second quarter. "It's the bellwether of all ETFs," said ETF Trends CEO Tom Lydon. "Because it's the biggest, the spreads between the bid and the ask are really, really tight," said Lydon.

  • Biotechnology Market on a Tear: 5 ETFs in Spotlight
    Zacks2 months ago

    Biotechnology Market on a Tear: 5 ETFs in Spotlight

    Increasing M&A deals, growing AI dominance and favorable regulatory tidings continue to accelerate the biotech market. Accordingly, ETFs with exposure to the sector continue to shine.

  • Health Day Checkup of Medical ETFs: 5 Top Picks
    Zacks2 months ago

    Health Day Checkup of Medical ETFs: 5 Top Picks

    M&A activity, approval of novel drugs and earnings growth in Q1 put healthcare ETFs in a decent spot.

  • A Spread of Top-Ranked ETFs That Crushed the Market in Q1
    Zacks2 months ago

    A Spread of Top-Ranked ETFs That Crushed the Market in Q1

    We are presenting a bunch of top performing ETFs of the first quarter with a solid Zacks ETF Rank 1 or 2 which are expected to outperform in the quarter ahead.

  • 5 biotech stocks that could be the next big winners
    MarketWatch3 months ago

    5 biotech stocks that could be the next big winners

    Biotech stocks are some of the most exciting investments on Wall Street. When one company develops a successful treatment for a complex condition, shares can surge overnight and attract buyout interest from Big Pharma. Case in point: Biotech giant Biogen (BIIB) imploded roughly 30% on Thursday after announcing it is canceling its Alzheimer’s drug efforts after poor drug trials.

  • Biotech Funds Could Generate Profitable Short Sales
    Investopedia3 months ago

    Biotech Funds Could Generate Profitable Short Sales

    Biotech funds have reached major resistance levels and could reverse in coming weeks, rewarding well-timed short sales.

  • Biogen shares tank nearly 30% after pulling key Alzheimer’s drug trial
    Yahoo Finance3 months ago

    Biogen shares tank nearly 30% after pulling key Alzheimer’s drug trial

    Biotech giant Biogen stock cratered 28% on Thursday, after the company announced that it would be pulling the plug on its ate-stage trial of its Alzeimer’s drug aducanumab.